Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Pharmaceuticals Holding Co (OTCPK:SHPMF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shanghai Pharmaceuticals Holding Co's Enterprise Value for the quarter that ended in Mar. 2026 was $9,280 Mil.
Shanghai Pharmaceuticals Holding Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,649 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co EV-to-EBIT Related Terms
Shanghai Pharmaceuticals Holding Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co EV-to-EBIT Chart
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's EV-to-EBIT falls into.
Shanghai Pharmaceuticals Holding Co's current Enterprise Value is $12,165 Mil.
Shanghai Pharmaceuticals Holding Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,649 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co (SHPMF) has a EV-to-EBIT of 7.37 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. This is 22% below median its historical median of 9.47. Over the past decade, Shanghai Pharmaceuticals Holding Co's EV-to-EBIT has ranged from 6.47 to 13.84. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #26 out of 94 companies in the Medical Distribution industry, placing it in the top 27.7%.
Is Shanghai Pharmaceuticals Holding Co's EV-to-EBIT too high?
Shanghai Pharmaceuticals Holding Co's current EV-to-EBIT of 7.37 is 22% below median its 10-year median of 9.47. Over the past 10 years, this metric has ranged from a low of 6.47 to a high of 13.84. The Medical Distribution industry median EV-to-EBIT is 11.48. Shanghai Pharmaceuticals Holding Co's value of 7.37 is 35.8% below this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #26 out of 94 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's EV-to-EBIT compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #26 out of 94 companies for EV-to-EBIT. This puts Shanghai Pharmaceuticals Holding Co in the upper half of its industry. The industry median EV-to-EBIT is 11.48. Shanghai Pharmaceuticals Holding Co's value of 7.37 is 35.8% below this benchmark. Historically, Shanghai Pharmaceuticals Holding Co's own EV-to-EBIT has ranged from 6.47 to 13.84 over the past decade. While the company's 10-year median is 9.47 vs. the industry median of 11.48, Shanghai Pharmaceuticals Holding Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.48, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current EV-to-EBIT of 7.37 is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current EV-to-EBIT is 7.37, which is 22% below median its own 10-year median of 9.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current EV-to-EBIT of 7.37. The stock's GF Value™ is $1.78, compared to a current price of $1.46 — trading 18% below its estimated fair value. The current EV-to-EBIT is 7.37, which is 22% below median its 10-year median of 9.47 and 35.8% below the Medical Distribution industry median of 11.48. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current EV-to-EBIT is 7.37 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $1.46 is trading 18% below its estimated GF Value™ of $1.78.
Key valuation signals for SHPMF:
EV-to-EBIT: 7.37 (22% below median its 10-year median of 9.47)
GF Value™: $1.78 vs. price of $1.46 (18% below fair value)
Industry Position: 35.8% below the Medical Distribution median (#26 of 94)
No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
78GF Score
Get the complete analysis for SHPMF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMF has been successfully added to your 
